Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacira Pharmaceuticals, Inc. on January 23, 2013. The filing details the completion of a private offering of convertible senior notes and the simultaneous repayment of an existing credit facility.
Key Financial Metrics
- Debt Issuance: Completed a private offering of $120 million in aggregate principal amount of 3.25% convertible senior notes due 2019.
- Net Proceeds: Approximately $115.3 million after deducting discounts, commissions, and estimated offering expenses.
- Debt Repayment: Repaid in full a $27.5 million credit facility (Oxford Credit Facility).
- Repayment Costs: Paid approximately $2.5 million in aggregate interest, prepayment fees, and end-of-term charges to terminate the Oxford Credit Facility.
- Interest Rate (New Notes): 3.25% per year, payable semiannually.
- Interest Rate (Old Facility): 9.75% per annum.
- Conversion Terms: Initial conversion rate of 40.2945 shares per $1,000 principal amount (approx. $24.82 per share), representing a 32.50% premium to the stock price on January 16, 2013.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements for revenue, profit, or cash flow. The primary material change is a significant restructuring of the company's capital structure:
- Debt Profile: Replaced a high-interest (9.75%) secured credit facility with a lower-interest (3.25%) unsecured convertible note structure.
- Liquidity: Increased net cash position by approximately $115.3 million from the new offering, partially offset by the $30 million used to retire the prior debt.
- Collateral: Removed the first priority security interest in substantially all assets (excluding intellectual property) that secured the Oxford Credit Facility.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds: The company utilized approximately $30 million of the new proceeds to retire the Oxford Credit Facility. The remaining proceeds are intended for general corporate purposes, though specific allocation details beyond the debt repayment are not quantified in this text.
Contingencies and Risks:
- Conversion Risk: Notes are convertible under specific conditions, including if the stock price exceeds 130% of the conversion price for 20 trading days in a quarter, or if the trading price of the notes falls below 98% of the product of the stock price and conversion rate.
- Redemption: The company may not redeem the notes prior to February 1, 2017. After that date, redemption is possible if the stock price remains above 130% of the conversion price, subject to a "make-whole" premium.
- Subordination: The new notes are senior unsecured obligations but are structurally junior to all indebtedness of the company's subsidiaries.
- Forward-Looking Statements: The filing includes a safe harbor disclaimer regarding risks related to the use of proceeds and general economic conditions.
Investor Verification Checklist
- Verify the exact amount of net proceeds remaining after the $30 million debt repayment and any other immediate expenditures.
- Confirm the current trading price of Pacira's common stock relative to the $24.82 conversion price to assess immediate conversion risk.
- Review the full Indenture (Exhibit 4.1) for specific covenants and events of default not summarized in the 8-K.
- Check subsequent filings for the actual use of the remaining net proceeds and any impact on the company's cash burn rate.
- Assess the impact of the removed security interest on the company's ability to secure future financing.